News Room provides integrated information to the media. In some instances, information on products or drug candidates under development may be included, but this is intended for members of the media, shareholders, and investors. The information is not intended for promotional or advertising purposes, or as medical advice, etc.
The Latest Media Conference
Tour of Manufacturing Building "FJ3" for Small and Mid-Size Molecule APIs at Fujieda Plant
Presentations:
Establishing the World Class Manufacturing System for
Small and Mid-Size Molecules to Drive the Realization
of TOP I 2030
Shinya Takuma,
Vice President, Head of Manufacturing Technology Div.,
Chugai Pharmaceutical Co., Ltd.
Pharmaceutical Technology for Mid-Size Molecule Drug
APIs
Dr. Kenji Maeda,
Head of API Process Development Dept., Pharmaceutical
Technology Div., Chugai Pharmaceutical Co., Ltd.
Introduction of Fujieda Plant, Chugai Pharma
Manufacturing Co., Ltd.
Kaichiro Koyama,
Head of Fujieda Plant, Chugai Pharma Manufacturing
Co., Ltd.
News
Topics about Advanced and sustainable patient-centric healthcare
We introduce Chugai's initiatives for "Patient-Centric," which we uphold as our highest priority "Core Value.
Topics about Sustainability
We will introduce our latest activities aimed at solving social issues through our business operations, in pursuit of "creating shared value" with society.
Features of the Strategic Alliance and Business Model “Alliance with Roche”
In 2002, Chugai started a strategic alliance with the Swiss company Roche, one of the world’s leading pharmaceutical companies. Under its unique business model, Chugai has realized its continuous growth.
While a member of the Roche Group, Chugai maintains its autonomous management and listing on the Tokyo Stock Exchange, enabling Chugai to focus on innovation with an emphasis on originality. This unprecedented business model contributes to enhancing Chugai’s corporate value and developing the Roche Group.
In this video, we will show the strategic alliance with Roche that forms the basis for this unique business model.
Features of the Strategic Alliance and Business Model “Transactions with Roche”
In 2002, Chugai started a strategic alliance with the Swiss
company Roche, one of the world’s leading pharmaceutical
companies.
Under its unique business model, Chugai has
realized its continuous growth.
In this video, we will present the financial impact that
transactions with Roche under the strategic alliance have on
Chugai.
The explanation will be divided into two parts:
“out-licensing of in-house products to Roche” and
“in-licensing of products from Roche.”